Towards Healthcare
Direct Oral Anticoagulants Market Captures USD 51.20 Billion in 2025

Direct Oral Anticoagulants (DOACs) Market Transformation Underway in 2025 as U.S. Patent Advances and Clinical Trials Strengthen Innovation

According to market projections, the global direct oral anticoagulants (DOACs) market is projected to reach US$ 102.36 billion by 2034, growing at a CAGR of 8%. Growth is driven by rising cardiovascular cases, preference for oral Factor Xa inhibitors, and expanding R&D in safer, AI-powered treatments.

Category: Therapeutic Area Insight Code: 5287 Format: PDF / PPT / Excel

The global direct oral anticoagulants (DOACs) market was estimated at US$ 43.9 billion in 2023 and is projected to grow to US$ 102.36 billion by 2034, rising at a compound annual growth rate (CAGR) of 8% from 2024 to 2034. DOACs are in high demand due to their use as anticoagulation in various cardiovascular diseases.

Direct Oral Anticoagulants (DOACs) Market Revenue 2023 - 2034

Key Takeaways

  • North America held a major revenue share of the market in 2024.
  • Asia-Pacific is expected to be the fastest-growing region during the forecast period.
  • By type, the oral factor Xa inhibitors segment held a dominant presence in the market in 2024.
  • By application, the atrial fibrillation segment accounted for a considerable revenue share of the market in 2024.

Market Overview

Direct oral anticoagulants, or DOACs, have rapidly emerged as appealing substitutes for the established anticoagulation standard of therapy, which includes vitamin K antagonists. A number of cardiovascular disorders can be prevented and treated using DOACs. In thromboembolic situations, DOACs have become the most popular therapeutic substitutes, offering patients and physicians safer, more convenient, and more effective treatment options. Clinicians must make more difficult judgments about the right drugs, therapy length, and use in particular patients as a result of DOACs' growing involvement.

  • In July 2025, VarmX announced that the U.S. Food and Drug Administration (FDA) provided clearance to begin a phase 3 trial of its VMX-C001 in patients requiring urgent surgery while on factor Xa DOACs. The EquilibriX-S trial is set to be conducted to evaluate how effectively VMX-C001 restores blood clotting in emergency surgical settings. (Source: Pharma Times)
  • In March 2025, Closed Loop Medicine Ltd. announced the expansion of its U.S. patent portfolio after receiving patent approval for its DOACs. The U.S. Patent Office extends its cardiometabolic capabilities into DOAC therapy, enabling more personalized and effective anticoagulation treatment. The patent supports AI-powered precision dosing for patients requiring DOACs. (Source: News Medical Life Science)

Market Dynamics

Market Opportunity: Growing Cases of Cardiovascular Diseases

Number of Deaths Due to CVDs., 2019 v/s 2030 (In Millions)

Despite improvements in disease prevention and treatment, cardiovascular diseases (CVDs) remain one of the top causes of death globally. The US economy is heavily impacted by NCDs, primarily CVDs, as the Centers for Disease Control and Prevention (CDC) noted in 2022. The healthcare system spends over $216 billion on NCDs, and the rising rate of workplace absenteeism and the resulting decreased productivity cost the US economy $147 billion. Healthcare expenses are severely impacted by thrombotic events in CVDs. The direct oral anticoagulants (DOACs) market is growing since anticoagulant usage is advised for the prevention of thrombotic events in a variety of cardiovascular conditions, such as stroke prevention in atrial fibrillation, therapy, and secondary prevention of acute coronary syndrome.

Market Challenge: Side Effects of DOACs

The direct oral anticoagulants (DOACs) market faces challenges due to the potential side effects of using DOACs. Like any drug, DOACs might have negative effects on certain persons. According to the patient information booklet that comes with your medication, various DOACs might have different adverse effects. Any anticoagulant may cause bleeding as a negative effect. Major bleeding is one of the more significant complications that can occur.

Growing R&D Activities as a Driver

The major growth factor of the direct oral anticoagulants (DOACs) market is the growing research and development activities. This enables researchers to identify disease progression and develop novel molecules of the same or different classes. Researchers focus on developing novel drugs with enhanced efficacy and reduced side effects. The increasing use of artificial intelligence (AI) and machine learning (ML) aids in predicting the pharmacokinetic and pharmacodynamic properties of drug-like candidates, expediting the drug screening process. Key players are deriving generic alternatives to existing brand-name drugs. This increases the affordability and accessibility of DOACs among large population groups. They are also determining the extended applications of DOACs for diverse disorders.

Regional Insights

North America Dominated the Direct Oral Anticoagulants (DOACs) Market

The dominance of North America is due to various factors, including advanced healthcare infrastructure, government support, growing investments in pharmaceuticals, and innovation & investments by key market players. The two major countries that contribute to the market’s growth are the U.S. and Canada.

Cases of CVD in the U.S., 2020 vs 2050 (In Millions)

The U.S. dominated the direct oral anticoagulants (DOACs) market in North America. The rising incidence of cardiovascular disorders is the main cause of the increase. Governments and major industry participants are taking initiatives to address the prevalence of CVDs in the United States. It is estimated that the annual healthcare expenses of cardiovascular risk factors, adjusted for inflation in 2022 US dollars, will treble from $400 billion to $1344 billion between 2020 and 2050. It is anticipated that the yearly cost of healthcare for cardiovascular problems will nearly triple, from $393 billion to $1490 billion, and that productivity losses will rise by 54%, from $234 billion to $361 billion.

Asia Pacific is Expected to Grow at the Fastest Rate

Asia Pacific is the largest region with a large population, which provides advantages by providing a large consumer base and a large manpower. The direct oral anticoagulants (DOACs) market is growing strongly in the region due to factors like innovation, investment in healthcare, and investments by international market players. Another major factor that contributes to the growth is the growing prevalence of CVDs in the region. Some of the countries that mainly contribute to the growth of the market include China and India. Japan, and South Korea.

There are an estimated 330 million CVD patients in China today, which includes 245 million cases of hypertension, 12.39 million cases of coronary heart disease, 8.9 million cases of heart failure, 5 million cases of pulmonary heart disease, 4.87 million cases of atrial fibrillation, 2.5 million cases of rheumatic heart disease, 2 million cases of congenital heart disease, 45.3 million cases of peripheral artery disease, and 13 million strokes.

The Government of India's Ministry of Health launched a public campaign on heart health in September 2023, today, World Heart Day. The campaign focuses on increasing awareness of the risk factors for hypertension, which can result in cardiovascular disease-related morbidity and early death. The government set the lofty goal of enrolling 75 million people with diabetes and hypertension in routine treatment by December 2025. It has already begun to show benefits and is billed as the largest primary healthcare initiative in the world. According to the National NCD Portal, 11 million people with diabetes and hypertension were receiving treatment as of August 2023.

Segmental Insights

Which Type Segment Dominated the Direct Oral Anticoagulants (DOACs) Market?

By type, the oral factor Xa inhibitors segment dominated the market. This segment dominated because many nations have now approved new oral anticoagulants for certain clinical reasons that specifically block either thrombin (dabigatran etexilate) or factor Xa (rivaroxaban, apixaban). These medications, in contrast to warfarin, have a quick beginning of action and a broad therapeutic range. Therefore, coagulation monitoring is not necessary. In addition to being more cost-effective than current treatments, these agents have the potential to enhance clinical outcomes and are more convenient for both patients and healthcare professionals.

For instance,

  • In February 2024, in nations that recognize the CE mark, Roche declared that it had introduced three new coagulation tests for the oral Factor Xa inhibitors: rivaroxaban, edoxaban, and apixaban.

How the Atrial Fibrillation Segment Held a Significant Share in the Direct Oral Anticoagulants (DOACs) Market?

By application, the atrial fibrillation segment held a significant share of the market. The most prevalent clinically relevant heart rhythm problem, atrial fibrillation (AF), is regarded as an epidemic of cardiovascular disease in the twenty-first century. According to projection studies, the number of people with AF is expected to increase to 15.9 million in America by 2050 and 17.9 million in Europe by 2060. Both North American and European recommendations advocate direct oral anticoagulants (DOACs) as the first-line treatment for atrial fibrillation patients in order to prevent ischemic stroke.

Latest Announcement by Industry Leaders

Dr. Hakim Yadi, CEO and Co-founder at Closed Loop Medicine, commented that establishing a strong and differentiated patent portfolio is central to the company’s leadership in AI-enabled personalized medicine. These patents reinforce the ability to deliver smarter, AI-enabled pharmacometric dosing solutions. (Source: https://www.news-medical.net/news/20250325/US-Patent-Office-grants-Closed-Loop-Medicine-key-patents-for-cardiometabolic-capabilities-in-GLP-1-and-Direct-Oral-Anti-Coagulants-(DOAC)-therapies.aspx)

Recent Developments

  • In February 2025, researchers from the University of Bath demonstrated that the risk of stopping anticoagulants in patients with atrial fibrillation is higher than the risk of bleeding. Stopping anticoagulation therapy in older patients may increase the risk of serious events, such as stroke and sudden death. (Source: Medical News- Life Science)
  • In October 2024, scientists from Amsterdam UMC unveiled positive results from their DOAC-CVT study, a large international cohort study. The study was conducted to analyze the response of DOACs in patients with central venous thrombosis (CVT). The results suggested that patients with CVT can be safely and efficaciously treated with DOACs. (Source: Amsterdam UMC)

Top Companies in the Direct Oral Anticoagulants (DOACs) Market

  • GlaxoSmithKline
  • Bayer AG
  • Viatris
  • Daiichi Sankyo
  • Bristol Myers Squibb Co
  • Accord Healthcare
  • Teva Pharmaceutical
  • Sandoz
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Ingelheim Pharmaceuticals Inc.
  • Pab Organics Pvt. Ltd.
  • Pfizer
  • Mylan
  • Apotex

Segments Covered in the Report

By Type

  • Oral Factor Xa Inhibitors
  • Direct Thrombin Inhibitors (DTIs)

By Application

  • Atrial Fibrillation
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Other

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Last Updated: 30 July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.

Learn more about Shivani Zoting

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

As a direct inhibitor of thrombin or factor Xa, direct oral anticoagulants (DOACs) are licensed to treat acute VTE and atrial fibrillation instead of heparins or VKA.

If the capsule contents are ingested without the shell, bioavailability is raised by 75% after a single dosage and 37% after successive doses.

DOACs are interesting choices for anticoagulation because they offer numerous benefits over VKAs, such as a fast start and offset of the anticoagulant effect, fixed dose, fewer medication and food interactions, and no monitoring required.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC, American Heart Association, NHS England, World Heart Federation.